Spore-ing change: Rua Bioscience psilocybin study targets meth addiction

Spore-ing change: Rua Bioscience psilocybin study targets meth addiction
Gisborne-based pharmaceutical company Rua Bioscience is hoping mushrooms can help cure meth addiction. (Image: Supplied)
Gregor Thompson
Rua Bioscience is exploring psilocybin-containing mushrooms’ potential in treating methamphetamine addiction.The clinical study, dubbed Tū Wairua (standing with strength and spiritual connectedness), intends to combine historic Māori practices with modern science to tackle meth addiction.The New Zealand Exchange-listed (NZX) and the Gisborne-based medical cannabis company announced Phase I of the new trial on Tuesday.“Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessio...

More Markets

Vulcan Steel leads as reporting season approaches
Markets Market Close

Vulcan Steel leads as reporting season approaches

The S&P/NZX 50 Index closed 55.30 points higher at 12,889.38.

Jamie Gray 15 Aug 2025
Competition law changing to allow 'beneficial collaboration'
Markets

Competition law changing to allow 'beneficial collaboration'

Confidential submissions to the Commerce Commission will get a 10-year OIA exemption.

Pattrick Smellie 15 Aug 2025
Small cap spotlight: Blackpearl Group
Markets Small Cap Wrap

Small cap spotlight: Blackpearl Group

Founder Nick Lissette says it's patriotic to be listed, but hard work.

NZ sharemarket rises, Vista Group shares fall
Markets Market Close

NZ sharemarket rises, Vista Group shares fall

The New Zealand sharemarket was up on Thursday as most stocks on the main board lifted.

Tom Raynel 14 Aug 2025